Combination therapy for the management of hypertension
The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.
1. A combination comprising:
a) at least one form of mecamylamine; and
b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the combination provides for a decreased therapeutically effective amount of each component as individually administered.
2. A combination comprising:
a) at least one form of mecamylamine; and
b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the mecamylamine is exo-S-mecamylamine.
3. A combination comprising:
a) at least one form of mecamylamine; and
b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the AT2 receptor inhibitor is losartan.
4. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the hypertension is angiotensin-induced hypertension.
5. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the administration further reduces one or more of cardiac hypertrophy or fibrosis.
6. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the at least one form of mecamylamine is exo-S-mecamylamine.
7. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the administration further prolongs the control of blood pressure at sustained dosage levels.
8. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the at least one form of mecamylamine and the at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof is administered concomitantly.
9. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the method further comprises diagnosing refractory hypertension by determining a subject's response upon administration.
10. A method for treating or inhibiting the onset of hypertension or refractory hypertension comprising administering:
a) at least one form of mecamylamine; and
b) at least one ACE inhibitor, AT2 receptor inhibitor, a renin inhibitor, a calcium channel blocker, or a combination thereof, wherein the AT2 inhibitor is losartan.